Eli Lilly Gets China Approval for Weight-Loss Pill
Eli Lilly has become the first drugmaker to win Chinese approval for a oral GLP-1 weight-loss medication. The milestone gives the company an edge over rival Novo Nordisk in the growing market for obesity treatments.
Xurve View
Insights:
Xurve View
Eli Lilly & Co secured approval in China on Thursday afternoon for orforglipron, becoming the first drugmaker to clear an oral GLP-1 weight-loss pill in the market. The milestone gives the Indianapolis-based company an early advantage over rivals in the world's second-largest pharmaceutical sector. Oral weight-loss treatments could capture patients who prefer to avoid weekly injections.
